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Abstract
HCV entry into cells is a multi-step and slow process. It is believed that the initial capture of HCV particles by
glycosaminoglycans and/or lipoprotein receptors is followed by coordinated interactions with the scavenger receptor class B
type I (SR-BI), a major receptor of high-density lipoprotein (HDL), the CD81 tetraspanin, and the tight junction protein Claudin-
1,ultimately leadingtouptakeandcellularpenetration ofHCVvialow-pHendosomes. SeveralreportshaveindicatedthatHDL
promotes HCV entry through interaction with SR-BI. This pathway remains largely elusive, although it was shown that HDL
neither associates with HCV particles nor modulates HCV binding to SR-BI. In contrast to CD81 and Claudin-1, the importance
of SR-BI has only been addressed indirectly because of lack of cells in which functional complementation assays with mutant
receptorscouldbeperformed. Here weidentified forthe firsttime twocell typesthatsupportedHCVppand HCVccentryupon
ectopic SR-BI expression. Remarkably, the undetectable expression of SR-BI in rat hepatoma cells allowed unambiguous
investigation of human SR-BI functions during HCV entry. By expressing different SR-BI mutants in either cell line, our results
revealed features of SR-BI intracellular domains that influence HCV infectivity without affecting receptor binding and
stimulation of HCV entry induced by HDL/SR-BI interaction. Conversely, we identified positions of SR-BI ectodomain that, by
altering HCV binding, inhibit entry. Finally, we characterized alternative ectodomain determinants that, by reducing SR-BI
cholesteroluptake and efflux functions, abolish HDL-mediated infection-enhancement. Altogether, we demonstratethatSR-BI
is an essential HCV entry factor. Moreover, our results highlight specific SR-BI determinants required during HCV entry and
physiological lipid transfer functions hijacked by HCV to favor infection.
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Introduction
Hepatitis C virus (HCV) infection is a leading cause of chronic
liver disease world-wide. With 180 million persistently infected
people, chronic hepatitis C infection, which induces end-stage liver
disease such as liver cirrhosis and hepatocellular carcinoma (HCC),
represents a major public health problem of high socio-economic
impact [1]. However, treatment options for chronic hepatitis C are
limited, and a vaccine for prevention against HCV infection is not
available. HCV is a positive strand RNA enveloped virus from the
Flaviviridae family. Viral attachment and entry—representing the
first encounter of the virus with the host cell—are major targets of
adaptive host cell defenses. Detailed understanding of the HCV
entry process should offer interesting opportunities for development
of novel therapeutic strategies to prevent or cure HCV infection.
HCV entry is thought to be a multi-step process (reviewed in
[2,3,4]). The interactions between envelope glycoproteins and
glycosaminoglycans might contribute to the primary binding of
virus particles to host cells. Because of the association of HCV with
low-density lipoproteins (LDL) in serum of infected patients [5],
the LDL receptor (LDLr) has also been proposed as an alternative
capture receptor [6]. Following this initial engagement, the
scavenger receptor class B type I (SR-BI) [7], the CD81
tetraspanin [8] and the tight junction protein Claudin-1 (CLDN1)
[9] may contribute to uptake and cellular penetration of HCV in a
clathrin-dependent manner [10,11]. Using HCVpp and HCVcc
infection assays as well as in vitro membrane fusion assays, HCV
entry was shown to occur in a pH-dependent manner
[12,13,14,15,16], through endocytosis of the viral particles
[10,11]. Like other Flaviviridae [17], the low endosomal pH may
induce conformational rearrangement of HCV glycoproteins,
leading to fusion of the viral membrane with that of the endosome.
The exact function of these molecules, and particularly SR-BI,
in HCV infection is still enigmatic. SR-BI, also called CLA-1, was
originally defined as a class B scavenger receptor [18] in a family
that includes CD36, LIMPII and SR-BII, an SR-BI isoform with
PLoS Pathogens | www.plospathogens.org 1 February 2009 | Volume 5 | Issue 2 | e1000310an alternate cytoplasmic tail [19]. SR-BI mediates binding and
lipid transfer from different classes of lipoproteins [20], particularly
high-density lipoprotein (HDL), accounting for its multiple
functions in cholesterol metabolism such as removal of peripheral
unesterified cholesterol, steroidogenesis and bile acid synthesis and
secretion. SR-BI stimulates the bi-directional flux of free
cholesterol (FC) between cells and lipoproteins, an activity that
may be responsible for net cholesterol efflux from peripheral cells
as well as the rapid hepatic clearance of FC from plasma HDL. In
hepatic cells, SR-BI also mediates the selective uptake of
cholesteryl ester (CE) from HDL, a process by which HDL CE
is taken into the plasma membrane without degradation of the
HDL particle [21]. Through lipid uptake, SR-BI increases cellular
cholesterol mass and alters cholesterol distribution in plasma
membrane domains [22,23].
SR-BI mediates binding of the E2 [7], one of the two
glycoproteins exposed at the surface of HCV particles, and, as a
multiligand lipoprotein receptor, can also induce binding of HCV
associated to LDL [24]. Intriguingly, we, and others, have
demonstrated that HDL enhances infectivity of HCVpp and
HCVcc [25,26,27,28,29,30]. This original mechanism is con-
trolled by the HCV glycoproteins, and, more particularly, by
conserved residues of the hypervariable region-1 (HVR1) [25,29],
a 27 amino-acid peptide located at the amino-terminus of E2.
HDL-mediated enhancement of infection clearly involves SR-BI
but this occurs neither through a direct binding of HDL to HCV
particles nor through increase of HCV binding to SR-BI
[25,27,29]. Since SR-BI locally increases cholesterol content of
cell membranes by mediating lipid transfer from HDL, it has been
proposed that HCV may exploit SR-BI physiological function to
achieve its entry processes [25,29]. However, direct evidence is
missing that, by providing a docking port to HCV particle and/or
by modulating post-binding events, SR-BI favors infection.
Indeed, in contrast to CD81 and CLDN1 whose implications
during HCV entry have been unambiguously demonstrated by
mutational analysis in cells that were rendered susceptible to HCV
entry upon their ectopic expression [9,12,13], the importance of
SR-BI has only been addressed indirectly because of lack of cells in
which similar complementation assays could be performed. Here
we identified two cell types, of rat and human origins, that
supported efficient HCV entry upon ectopic expression of SR-BI.
Through the design of SR-BI mutants, i.e., in the extracellular and
the cytoplasmic domains, we unravel important features of SR-BI
functions regarding its involvement during HCV entry.
Results
Susceptibility to HCVpp and HCVcc entry upon ectopic
expression of HCV receptors
Challenging the notion of liver tropism of HCV, most HCV
receptors isolated so far are broadly expressed in different tissues,
including those in which HCV does not replicate [2,3,4].
Particularly, the broadness of SR-BI expression makes difficult
the investigation of the functional properties of this molecule in
HCV infection, owing to the paucity of SR-BI-negative human
cell lines in which susceptibility to HCV entry could be obtained
upon ectopic expression. Furthermore, efficient SR-BI down-
regulation in susceptible cell types, such as Huh-7 cells, is difficult
to achieve without compromising cell viability (MD, DL, BB and
FLC, data not published) and has raised different results between
studies [14,25,29,31,32]. To overcome these difficulties, we
screened a panel of human and rodent cell lines for absence or
low SR-BI expression (Table 1). Aiming to design functional
complementation assays, we ectopically expressed in these cells
HCV receptors by transduction with a set of selectable retroviral
vectors encoding human CD81, CLDN1 or SR-BI and, upon
appropriate selection, we challenged these cells with HCV pseudo-
particles (HCVpp). We detected one human liver endothelial cell
line, SK-Hep1, and one rat hepatocarcinoma cell line, BRL3A,
that became susceptible to entry with HCVpp-H77 (Table 1) and
with HCVpp of other genotypes (Figure S1C) upon ectopic
expression of SR-BI, provided hCD81 and hCLDN1 were also co-
expressed, endogenously or ectopically (Figure 1 and Figure S1).
While non hepato-carcinoma cells of human origin like e.g., 293T
cells, have been rendered susceptible to HCV entry upon ectopic
expression of hCLDN1 [9], this is the first report of a non human
cell line that can be functionally complemented by HCV
receptors, allowing efficient HCV entry.
Over-expression of hSR-BI in SK-Hep1-CLDN1 cells that
express very low endogenous SR-BI levels (Figure 1A and Figure
S1A) resulted in ca. 10-fold increased HCVpp titers, i.e., titers that
were only 2-fold lower than those obtained in Huh-7 cells
(Figure 1B and Figure S1D). In contrast, no or undetectable
expression of endogenous rat SR-BI could be detected by
immunoblotting and by RT-qPCR in BRL3A cells (Figure S1A
and S1B, Protocol S1). Furthermore, no or hardly detectable HCV
entry could be found in BRL3A cells ectopically expressing hSR-
BI only or expressing both hCD81 and hCLDN1 (BRL3A-CD81-
CLDN1 cells), despite full entry susceptibility of control pseudo-
particles pseudotyped with VSV-G glycoprotein (Figure 1B and
Figure S1D). Expression of hSR-BI in BRL3A-CD81-CLDN1
cells allowed HCVpp entry at titers similar to those detected in
PLC/PRF/5 and Hep3B human hepato-carcinoma cells
(Figure 1B), used in previous reports [12,13,33,34], and ca. 8-
fold lower than those obtained with Huh-7 cells (Figure 1B), which
are the most susceptible to HCV entry [12,13,14,33]. Of note, co-
expression of hCD81, hCLDN1 and/or hSR-BI did not modify
total (Figure S1A) or cell surface (Figure S2) expression levels of
either of these entry factors. Hence, our results unambiguously
demonstrated for the first time that expression of SR-BI - in
combination with CD81 and CLDN1 - is required to allow HCV
entry and support the notion that hSR-BI is an essential entry
factor of HCV.
We used these complementation assays to characterize the
properties of hSR-BI in HCV entry. HDL, the main ligand of SR-
Author Summary
More than 180 million people are chronically infected by
hepatitis C virus (HCV), a leading cause of liver failure and
cancer, stimulating the need to fully define the biology of
HCV infection for developing novel and effective thera-
peutics. During the first steps of infection, the virus is
taken up and penetrates hepatocytes. HCV entry is
thought to be a coordinated multi-step process mediated
by specific factors, including CD81, Claudin-1, and the
scavenger receptor BI (SR-BI). Whereas the involvement of
CD81 and Claudin-1 was demonstrated by rendering
susceptible cells that are otherwise refractory, SR-BI
complementation assays were lacking, raising questions
as to its functions during HCV entry. Here, we identify one
hepatoma rat cell line, in which SR-BI complementation
assay and targeted mutagenesis could be performed. We
therefore demonstrate that SR-BI is an essential HCV entry
factor. Our results shed light on SR-BI intracellular domain
functions in HCV entry, and, further, emphasize the
remarkable capacity of HCV to hijack the lipid transfer
function of SR-BI, hence favoring infection.
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[26,27,30] in SR-BI-positive human cells that are susceptible to
HCV entry like, e.g., Huh-7, HepG2-CD81, PLC/PRF/5, SW13
or Hep3B cells. We found that HCVpp entry into both BRL3A-
CD81-CLDN1-SR-BI and SK-Hep1-CLDN1-SR-BI cells was
stimulated by HDL to levels comparable to those detected in
human hepatoma cells (Figure 1C). No change of cell surface (co)-
expression of hSR-BI and/or hCD81 could be detected upon
incubation of these cells with HDL (Figure S2 and data not
shown).
Next, we confirmed the above findings using cell culture-derived
HCV (HCVcc). In comparison to HCVcc infection of Huh-7.5
cells, for which viral infectious titers (above 1610
6 i.u./ml) could
be assessed by immunostaining for Core protein, the same viral
stocks resulted in lower infectivity levels in SK-Hep1-CLDN1-SR-
BI target cells (data not shown), precluding accurate determination
of infectious titers by immuno-detection. Therefore, we used a
sensitive and quantitative real-time RT-PCR (RT-qPCR) assay to
measure changes in HCV RNA at 4 hr, 12 hr and 72 hr post-
infection with HCVcc. Inoculation of HCVcc on SK-Hep1-
CLDN1 and SK-Hep1-CLDN1-SR-BI cells yielded strong RT-
qPCR signals at 4 hr post-infection, indicating binding and/or
capture of viral particles [9], that progressively declined with 10–
30 fold loss at 12 hr (Figure 2A). Yet, while HCV RNA decreased
again by ca. 15-fold in the parental SK-Hep1-CLDN1 cells at
72 hr, the HCV RNA levels increased in SK-Hep1-CLDN1-SR-
BI cells at 72 hr vs. 12 hr post-infection but were strongly reduced
when such target cells were treated during 72 hr with HCV
replication inhibitors (BILN2061, an NS3 protease inhibitor, or
29-C-methyl-adenosine, an NS5B polymerase inhibitor)
(Figure 2A). Altogether, these results indicated that the detection
of HCV RNAs revealed true HCVcc entry of these cells, leading
to viral replication, rather than just residual cell attachment of
viral particles. Overall, the co-expression of SR-BI and CLDN1 in
SK-Hep1 cells allowed ca. 10 to 20 fold increased HCV RNA
detection at this 72 hr time point as compared to SK-Hep1 cells
expressing CLDN1 alone or none of these entry factors (Figure 2B),
consistent with results obtained with HCVpp (Figure 1B and
Figure S1D). Importantly, addition of HDL during infection could
stimulate HCV RNA detection in SR-BI-expressing SK-Hep1-
CLDN1 cells but not in the parental cells (Figure 2B).
In previous studies [25,29,35], it was proposed that one of the
mechanisms by which HDL enhances infection could involve SR-
BI physiological activity. To address this possibility, we first sought
to demonstrate whether SR-BI expressed in the BRL3A and SK-
Hep1 cellular backgrounds was functional and could mediate lipid
transfer, i.e., selective uptake of
3H-CE-labelled HDL [36] and
efflux of
3H-cholesterol to phospholipid cholesterol acceptors [37].
As shown in Figure 2C, while BRL3A-CD81-CLDN1 cells could
not or hardly mediate lipid transfer most likely owing to
undetectable SR-BI levels (Figure S1A and S1B), ectopic
expression of hSR-BI in these cells resulted in efficient lipid
uptake and efflux, as compared to rat hepatoma Fu5AH cells
expressing rat SR-BI (Figure S1A and S1B) used as positive
controls. Likewise, over-expression of hSR-BI in SK-Hep1-
CLDN1 cells resulted in efficient cholesterol efflux as compared
to parental cells (Figure 2C). Importantly, these results were
consistent with the restoration of HDL-mediated enhancement of
HCV entry upon ectopic expression of SR-BI (Figure 1C and
Figure 2B).
Altogether, these results established that BRL3A-CD81-
CLDN1 and SK-Hep1-CLDN1 cells provide original and useful
Table 1. HCVpp entry in receptor-complemented target cells.
Cell Lines Tissue HCVpp Entry
a hCD81
b hCLDN1
c hSR-BI
d
Huh-7 Human hepatoma ++ + + +
PLC/PRF/5 Human hepatoma ++ + + +
Hep3B Human hepatoma ++ + +
CHO Chinese hamster ovary 22 2 2
CHO-CD81-CLDN1-SR-BI Chinese hamster ovary 2 ++ ++ ++
MDCK Dog kidney epithelium 22 2 2
MDCK-CD81-CLDN1-SR-BI Dog kidney epithelium 2 ++ ++ ++
Hepa1.6 Mouse hepatoma 22 2 2
Hepa1.6-CD81-CLDN1-SR-BI Mouse hepatoma 2 ++ + +
XC Rat fibrosarcoma 22 2 2
XC-CD81-CLDN1-SR-BI Rat fibrosarcoma 2 ++ +
BRL3A Rat hepatoma 22 2 2
BRL3A-CD81-CLDN1-SR-BI Rat hepatoma ++ + +
SK-Hep1 Human liver endothelium 6 + 2 6
SK-Hep1-CD81-CLDN1-SR-BI Human liver endothelium ++ + + + +
aHCVpp entry of genotype 1a (H77) harbouring the GFP marker gene. (++), titres higher than 10
5 IU/ml; (+), titres between 10
3 and 10
5 IU/ml; (6), titres between 10
2
and 10
3 IU/ml; (2), titres lower than 10
2 IU/ml, which corresponds to the threshold of detection of infected cells by FACS analysis.
bDetection of human CD81 using JS-81 antibody on the surface of the indicated cells by flow cytometry. (2), MFI (mean fluorescent intensity) shift of 1; (+), MFI shift
between 1 and 50; (++), MFI shift over 50.
cDetection of human Claudin-1 (CLDN1) in lysates of the indicated cells by immuno-blotting with mouse anti-Claudin-1 antibodies (Interchim). (2), signal intensity 5-
fold lower than that detected in Huh-7 cells; (+), signal intensity between 5-fold lower and 5-fold higher than that detected in Huh-7 cells; (++), signal intensity 5-fold
higher than that detected in Huh-7 cells.
dDetection of human SR-B1 using the CLA-1 antibody on the surface of the indicated cells by flow cytometry. (2), MFI shift of less than 2; (6), MFI shift between 2 and 6;
(+), MFI shift between 6 and 20; (++), MFI shift over 20.
doi:10.1371/journal.ppat.1000310.t001
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time mutagenetic approaches possible to study the roles of SR-BI
in HCV entry.
Function of SR-BI intracellular domain
We tested a panel of well-characterized SR-BI mutants in
receptor complementation assays in order to address the properties
of its intracellular and extracellular domains. Upon introduction in
BRL3A-CD81-CLDN1 or SK-Hep1-CLDN1 cells, each SR-BI
mutant was studied for its capacity to mediate HCV-E2 binding,
HCV entry and HDL-induced infection-enhancement. Because
some mutations introduced into human SR-BI were originally
characterized in the murine ortholog, which shares 79% identity
with human SR-BI (data not shown), we also characterized lipid
uptake and efflux mediated by these human SR-BI mutants. To
address the functions of the SR-BI intracellular domain, we
expressed several SR-BI mutants or isoforms in BRL3A-CD81-
CLDN1 and SK-Hep1-CLDN1 cells. By adjusting the input of
vectors used to transduce the mutant/chimeric receptors in these
cells, we obtained cell surface expression levels comparable to that
of wt SR-BI as detected by FACS analysis (Figure 3A). To
investigate the capacity of these modified SR-BI receptors to
mediate binding of HCV surface glycoproteins (Figure 3A), we
used a soluble recombinant form of HCV E2 glycoprotein (sE2),
which harbors determinants of binding to CD81 [38,39] and to
SR-BI [7]. Of note, sE2-based binding assays may not fully
represent all the binding parameters of HCV particles to CD81
[9,40,41,42]. Yet, we decided to use this assay since in previous
studies [27,35,43], we found that SR-BI-binding of HCVpp
parallels that of sE2 although the latter is more sensitive than
binding of HCVpp. Importantly, all these different target cells
induced comparable entry levels of control viral particles
harboring the VSV-G glycoprotein (VSV-Gpp), with less than
30% variation of VSV-Gpp titers as compared to those detected
on wt SR-BI-expressing cells (Figure 3B). Note that although
Figure 3B provides the raw data, the small differences of VSV-
Gpp titers between the different SR-BI mutant-expressing cell
lines could be used to normalize HCVpp infectivity.
First, we investigated the HCV entry properties of a chimeric
SR-BI/CD36 receptor [44,45,46], in which the two transmem-
brane domains and cytoplasmic tails of SR-BI were replaced by
those of CD36, a close homolog of SR-BI that mediates high-
affinity HDL binding but not efficient lipid transfer [46]. Cells
expressing wt CD36 did not induce sE2 binding (Figure 3A), as
reported previously [7], nor did they allow HCVpp entry
(Figure 3B). In contrast, as compared to wt SR-BI, the SR-BI/
CD36 chimera mediated about 3-fold reduced sE2 binding, in
agreement with the 3-fold reduction of HCVpp entry, after VSV-
Gpp normalization. Despite this reduced basal HCV entry, this
mutant receptor allowed HDL-mediated infection-enhancement
at levels similar to those obtained with wt SR-BI (Figure 3C).
To examine further the involvement of the SR-BI endodomain
in HCV entry, we expressed in BRL3A-CD81-CLDN1 cells SR-
BI forms harboring alterations of its C-terminal cytoplasmic tail,
which contains signals associated to SR-BI expression, localization
and/or function: DCterm, a SR-BI mutant lacking the C-terminal
cytoplasmic tail [45], and SR-BII, an alternative mRNA splice
variant of SR-BI with an entirely different cytoplasmic C terminus
that promotes more rapid HDL/SR-BII endocytosis as compared
to SR-BI and alternative signaling events [47,48]. Both forms of
SR-BI were previously shown to mediate efficient binding of HDL
[45,47] and to induce lipid transfer (Figure 3D). We adjusted SR-
BII cell surface expression to levels similar to those of SR-BI, but
albeit all our efforts the expression levels of the DCterm mutant
remained two-fold reduced (Figure 3A). Similar to results obtained
with the SR-BI/CD36 chimera, these altered SR-BI receptors
induced reduced sE2 binding (by 2–3 fold) and HCVpp entry (by
2-fold) but wild type level of HDL-induced infection-enhancement
(Figure 3A–3C). Altogether, the results obtained with SR-BII, SR-
BI/CD36 or DCterm mutants indicated that while the cytoplasmic
tail of SR-BI does not seem to be involved in stimulation of
infection by HDL, it could influence the basal HCV entry
efficiency. Furthermore, the results on sE2 binding suggested that
the level of cell attachment of viral particles was altered for these
mutants, which could reflect alterations of receptor affinity,
density, localization and/or turnover at the plasma membrane.
We therefore sought to investigate specific determinants of SR-
BI cytoplasmic tail that could modulate HCV entry. We first
generated a mutant SR-BI receptor, DAKL, in which we removed
a carboxy-terminal motif of SR-BI that mediates interaction with
PDZKI or CLAMP [49]. PDZKI is a four-PDZ-domain-
containing protein that is associated with SR-BI in hepatocytes
and that may stabilize SR-BI in the sinusoidal plasma membrane
by modulating its intracellular transport, localization, assembly
and scaffolding [49,50]. Compared to wt SR-BI, we found that the
deletion of PDZKI-associating motif slightly reduced mutant
receptor expression and sE2 binding by less than 2-fold but had no
or minor influence on HCV entry and HDL-mediated infection
enhancement (Figure 3). Furthermore, when PDZK1 was
knocked-down in Huh-7 cells using siRNAs, we found that the
PDZK1 down-regulated cells induced HCV entry and infection-
enhancement at levels identical to those detected in unmodified
Huh-7 cells (Figure S3). Thus, PDZK1 down-regulation had
almost no effect on HCV entry, in agreement with the results of
AKL motif deletion. Next, we generated alternative cytoplasmic-
tail mutants: SES, in which the endocytosis motif of SR-BII was
functionally introduced [51], and 2CS, in which the two acylation
sites of the SR-BI carboxy-terminal cytoplasmic tail were mutated
[46]. Like the DAKL mutant, these alternative mutants allow
efficient HDL binding [46,51]. Despite similar cell surface
expression and sE2 binding, as compared to wt SR-BI
(Figure 3A), the SES and 2CS mutants induced about 2-fold
Figure 1. HCVpp entry upon ectopic hSR-BI co-expression with other HCV receptors. (A) Endogenous and/or ectopic expression of hSR-BI
and hCD81 in BRL3A, SK-Hep1, and Huh-7 cells was determined by flow cytometry. Parental cells were stained with hSR-BI (CLA-1 mAb, upper panel)
or hCD81 (JS81 mAb, lower panel) antibodies (gray lines). The background of fluorescence was provided by staining the cells with the secondary
antibodies only (dotted lines). Ectopic expression of hSR-BI in BRL3A and SK-Hep1 cells or of hCD81 in BRL3A cells was determined using the same
antibodies (black lines). The results are representative of three independent experiments. (B) Results of HCV entry assays on BRL3A and SK-Hep1 cells
ectopically expressing the indicated HCV receptors, and on PLC/PRF/5, Hep3B, and Huh-7 human hepatoma cells, endogenously expressing CD81,
CLDN1, and SR-BI, using HCV pseudo-particles harboring H77-E1E2 glycoproteins (HCVpp), control viral particles harboring the VSV-G glycoprotein
(VSV-Gpp; diluted 1/100), or no glycoprotein (noENVpp). The viral particles were produced in cell culture media devoid of serum lipoproteins. Results
display average infectious titers, expressed as GFP IU/ml (mean6SD; n=3). ND, not determined. (C) HCV entry assays using HCVpp produced in
serum-free medium in the presence of 6 mg/ml cholesterol-HDL. The results show the fold increases of infection (mean6SD; n=3) determined by
calculating the ratios between average infectious titers determined in the presence or absence of HDL. No changes of infectivity with VSV-Gpp
control particles were detected under these experimental conditions (data no shown), as reported previously [25].
doi:10.1371/journal.ppat.1000310.g001
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measuring intracellular HCV RNA level at 4, 12, and 72 hr post-infection, in SK-Hep1 cells ectopically expressing CLDN1 vs. CLDN1 and SR-BI, using cell
culture–produced HCVcc in the absence or in the presence of NS3 protease inhibitor and NS5B-dependent RNA synthesis inhibitor (BILN2051 and 29-
C-methyl-adenosine, respectively, kindly provided by FV Chisari). Results are standardized with respect to the HCV RNA level obtained at 72 hr on
non-treated SK-Hep1-CLDN1-SR-BI cells (mean6SD; n=3). Intracellular HCV RNA levels of SK-Hep1-CLDN1-SR-BI was on average 440-fold lower than
HCV RNA levels measured in Huh7.5 cell (4.7610
362.4610
2 genome copies per mg cellular mRNA) using the same HCVcc supernatants. (B) Results of
HCVcc entry assays, assessed at 72 hr post-infection, in SK-Hep1 cells ectopically expressing the indicated HCV entry factors, using cell culture–
produced HCVcc in the absence (white bars) or presence (black bars) of 0.6 mg/ml cholesterol-HDL. Results are standardized with respect to HCV RNA
level obtained in the absence of HDL on wt SR-BI–expressing SK-Hep1-CLDN1 cells (mean6SD; n=5). Similar experiments in BRL3A-CD81-CLDN1-SR-
BI cells allowed detection of HCV RNA at 72 hr, which was specifically increased upon treatment with HDL, and revealed differences upon expression
of HCV entry factors (data not shown) consistent with the results obtained with HCVpp. However, kinetic experiments and use of replication
inhibitors did not allow firm demonstration of HCV replication in these cells. (C) Dose-response curves for the SR-BI–dependent free cholesterol efflux
and for HDL-CE uptake determined in BRL3A-CD81-CLDN1 and SKHep1-CLDN1 cells ectopically expressing, or not, hSR-BI, or in Fu5AH cells
expressing high endogenous levels of rat SR-BI. Cholesterol efflux is expressed as the percentage of total labelled
3H-cholesterol released to the
medium. Selective HDL-CE uptake is expressed as the percentage of labelled HDL-CE delivered to cells per mg of cell protein. The values represent the
means 6SD of three experiments.
doi:10.1371/journal.ppat.1000310.g002
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endocytic trafficking and/or membrane localization of SR-BI in
HCV entry.
While these results were obtained in a rat hepato-carcinoma
background, they were largely confirmed in the human back-
ground of SK-Hep1-CLDN1 cells expressing the different SR-BI
mutants (Figure S4). Furthermore, we tested a subset of these SR-
BI mutants in HCVcc infection assays. While CD36 expression in
SK-Hep1-CLDN1 cells did not induce infection of HCVcc, the
SR-BI/CD36 chimera and the SES mutant were functional, but,
for the latter, infection was reduced in comparison to wt SR-BI
(Figure 4), in line with results obtained with HCVpp infection
assays. Finally, we found that HDL stimulated HCVpp entry
(Figure 3 and Figure S4) and HCVcc (Figure 4) at similar levels for
SR-BI cytoplasmic tail mutants as compared to wt SR-BI.
Altogether, these results indicated that the C-terminal cytoplasmic
tail of SR-BI modulates the basal HCV entry process, but seems
not to influence HDL-mediated infection-enhancement. This
latter observation is consistent with the fact that the SR-BI C-
terminal mutants mediated efficient lipid transfer (Figure 3D).
Functions of the extracellular domain
To address the functions of the SR-BI ectodomain, we
expressed SR-BI mutants that exhibited reduced HDL binding
and/or lipid transfer properties. The capacity of either mutant to
mediate sE2 binding, HCV entry and HDL-mediated infection-
enhancement was compared with wt SR-BI or with the E210G
ectodomain mutant, exhibiting wt lipid transfer properties
(Figure 5D). First, we expressed a shorter isoform of SR-BI (SR-
BI-Short), produced by alternative splicing of SR-BI mRNA that
removes 100-amino-acids of the ectodomain [18], and the M159R
point mutant, targeting a motif conserved between mouse and
human SR-BI that has been shown to reduce HDL binding and
lipid transfer [52]. The decreased levels of lipid uptake and efflux
were verified for each mutant (Figure 5D). Upon expression in
BRL3A-CD81-CLDN1 cells, these modified SR-BI receptors
mediated no (SR-BI-Short) or hardly detectable (M159R) sE2
binding (Figure 5A) and reduced HCVpp entry by over 10-fold, in
comparison to wt SR-BI (Figure 5B). These results therefore
highlighted the importance of E2 attachment to the SR-BI
ectodomain in the HCV entry process. Moreover, these mutants
were unable to induce infection-enhancement when HDL was
added during HCVpp infection (Figure 5C), which could be due to
their inability to mediate HCV binding or, alternatively, from
their inability to bind HDL and/or to mediate lipid transfer.
BLTs (block lipid transfer; BLT-1 to BLT-4) are small lipid
transport inhibitors originally identified in a high-throughput
chemical screen of intact mSR-BI-expressing cells [53]. They
inhibit SR-BI-dependent selective cholesterol uptake and efflux
from and to HDL, but do not block HDL binding. We, and others,
previously showed that BLTs also inhibit HDL-mediated HCV
infection-enhancement, which, together with alternative results
using SR-BI blocking antibodies or SR-BI down-regulation,
suggested the possibility that the SR-BI physiological activity is
involved during HCV entry [25,29]. Surprisingly, here we found
that BLT-4, characterized in several previous studies [25,29],
inhibited sE2 binding to SR-BI-expressing BRL3A (Figure 6) and
CHO (data not shown) cells, at the same concentrations as those
that provedto be effective for HCVentry inhibition, i.e., 15–50 mM
[25,27,29]. Similar inhibition ofHCVpp infectivityandsE2binding
was detected with other BLTs (data not shown). While sE2 readily
bound BRL-CD81-CLDN1 cells, no inhibition of sE2 binding by
BLTs could be detected on those cells (Figure 6 and data not
shown). Moreover, while co-expression of CD81 and SR-BI
increased sE2 binding as compared to BRL3A cells expressing
either entry factor, BLT-4 reduced sE2 binding to BRL-CD81-
CLDN1-SR-BI at the levels detected on BRL-CD81-CLDN1 cells
(Figure 6). These results indicated that BLTs specifically inhibited
sE2bindingtoSR-BI.Moreover,HDLdidnotincreasesE2 binding
to either SR-BI or CD81 and did not modify inhibition of sE2
binding to SR-BI by BLT-4 (Figure 6). The unexpected finding that
BLTs inhibit sE2/SR-BI binding further lent support for a
requirement of sE2 binding to SR-BI for HCV entry. However,
since the use of BLTs could not unambiguously demonstrate that
HDL-mediated infection-enhancement requires SR-BI-dependent
lipid transfer, next, we expressed and analyzed effects of SR-BI
ectodomain mutants E418R, Q402R and Q402R/E418R that
havereducedlipiduptakeproperties[52,54],asshowninFigure5D.
Similar levels of cell surface expression for either mutant could be
detected by FACS analysis, as compared to wt SR-BI (Figure 5A).
These SR-BI mutants exhibited 5–15 fold reduced sE2 binding
(Figure 5A), whichwascorrelated with a lowerinfectivityofHCVpp
(Figure5B),inagreementwithresultsobtainedwiththeM159Rand
SR-BI-Short mutants. When HDL was added during the HCV
entry assay, we found that the extent of infection-enhancement
(Figure 5C)was correlated to the capacity of these SR-BI mutants to
mediate lipid uptake (Figure 5D). For example, while E418R that
shows 60% reduced lipid uptake capacity induced wild-type HDL-
mediated infection-enhancement, the most disabled lipid transfer
mutants, Q402R and Q402R-E418R, had lost almost all infection-
enhancement capacity (Figure 5C and 5D). Collectively, the results
demonstrated that SR-BI functions as an HCV entry factor by
providing both cell surface binding sites and lipid uptake activity.
Importantly, these different mutants had reduced HDL binding
levels [52,54], which could not unambiguously discriminate
between altered HDL binding vs. reduced lipid transfer, the
Figure 3. HCVpp entry in BRL3A-CD81-CLDN1 cells expressing SR-BI intracellular domain mutants. (A) Cell surface expression (white
bars) and sE2 binding (black bars) of SR-BI mutants/isoforms was determined using anti-SR-BI antibody (CLA-1 mAb) and soluble E2 protein (sE2),
respectively. The results of cell surface expression, analyzed by flow cytometry of BRL3A-CD81-CLDN1 cells transduced with retroviral vectors carrying
the indicated SR-BI mutants, are expressed as the average percentages of GEOmean (geometric mean) fluorescence shifts (mean6SD; n=3) detected
between mutant receptor–expressing cells and parental (—) cells, relative to cells expressing wild-type SR-BI (ca. 20-fold of GEOmean shift, see
Figure 1A) set to 100. The results of sE2 binding are expressed as the average percentages of GEOmean fluorescence shifts (mean6SD; n=3)
detected in parental BRL3A cells (—) or in BRL3A cells only expressing the indicated SR-BI mutants that were incubated with sE2-containing medium
vs. sE2-free medium, relative to cells expressing wild-type SR-BI (ca. 10-fold GEOmean shift, see Figure 6) set to 100. Cell surface expression of SR-BI
mutants in these latter cells was similar to that detected in the SR-BI–expressing BRL3A-CD81-CLDN1 cells (data not shown). Cell surface expression of
CD36 (*, data not shown) was verified using a CD36 antibody (FA6-152, abcam). (B) Effect of SR-BI mutations on infectivity of HCVpp produced in
serum-free media. The results of infectivity (mean6SD; n=5) are expressed relative to the infectious titers of HCVpp or of control VSV-Gpp particles
determined on wt SR-BI–expressing BRL3A-CD81-CLDN1 cells (input ca. 10
4 GFP IU) set to 100. (C) Results of HCVpp infection-enhancement induced
by HDL (6 mg/ml cholesterol-HDL), expressed as ratios between average infectious titers determined in the presence or absence of HDL (mean6SD;
n=5). No changes of infectivity of VSV-Gpp control particles were detected under these experimental conditions (data not shown), as reported
previously [25]. (D) Relative capacities of SR-BI mutants to mediate HDL-CE uptake (black bars) and free cholesterol efflux (white bars) relative to wt
SR-BI set to 100 (mean6SD; n=3). ND, not determined.
doi:10.1371/journal.ppat.1000310.g003
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by SR-BI. Therefore, we next generated the N173Q and G420H-
G424H mutants that have impaired lipid transfer but normal
HDL binding [55,56,57]. These mutants induced ca. 10-fold
reduced sE2 binding (Figure 5A), which resulted in ca. 4–5 fold
reduced infectivity (Figure 5B). Interestingly, while the N173Q
mutant poorly induced HDL-mediated infection-enhancement,
the G420H-G424H failed to support stimulation of infection
induced by HDL (Figure 5C), in agreement with their strongly
reduced capacity to mediate lipid transfer (Figure 5D). These data
further supported the notion that the lipid transfer functions of
SR-BI are required for HCV entry enhancement.
These results, obtained in the background of BRL3A rat cells,
were confirmed in the human background of SK-Hep1 cells
(Figure S4). Furthermore, we performed HCVcc infection assays
of SK-Hep1-CLDN1 cells expressing a subset of mutants of SR-BI
extracellular domain (i.e., Q402R-E418R, N173Q and G420H-
G424H) (Figure 4). We confirmed that these mutant receptors
reduced infection in comparison to wt SR-BI, but completely
abolished HDL-mediated infection enhancement.
Discussion
Several lines of evidence suggested that SR-BI plays a
prominent role in HCV entry into cells. First, SR-BI provides
both direct and ApoB-mediated interaction with HCV particles
[7,24,58]. Second, antibody blocking or down-regulation of SR-BI
inhibit HCV entry in permissive cells [12,14,25,26,29,59]. Third,
Figure 4. HCVcc entry in SK-Hep1-CLDN1 cells expressing SR-BI mutants. The SR-BI mutants tested were the SR-BI/CD36 chimera and the
SES mutants, altering SR-BI intracellular domain, the Q402R/E418R, N173Q, and G420H-G424H mutants, altering SR-BI ectodomain. (A) Effect of SR-BI
mutations on infectivity of HCVcc produced under standard conditions and assessed by measuring intracellular HCV RNA level at 72 hr post-infection
(see Figure 2A). The results of infectivity (mean6SD; n=3) are expressed relative to HCVcc infection of wt SR-BI–expressing SK-Hep1-CLDN1 cells,
which was set to 100. (B) Results of HCVcc infection-enhancement induced by HDL (0.6 mg/ml cholesterol-HDL) on wt SR-BI–expressing SK-Hep1-
CLDN1 cells, expressed as ratios relative to infection in the absence of HDL of the same cells set to 100 (mean6SD; n=3). Similar experiments in
BRL3A-CD81-CLDN1 cells expressing these SR-BI mutants were performed (data not shown) and were consistent with the results obtained in SK-
Hep1-CLDN1 cells.
doi:10.1371/journal.ppat.1000310.g004
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in human hepatocarcinoma target cells [25,26,27,28,29,35].
Finally, using small molecules that inhibit the selective lipid
transfer functions of SR-BI, named BLTs [53], it was proposed
that besides providing a docking site for HCV particles, SR-BI
physiological property, i.e., cholesterol uptake and/or efflux, could
be exploited during HCV entry [25,29]. Yet, despite this indirect
evidence, functional complementation assays addressing the
implication of SR-BI during HCV entry were lacking since no
cell type in which SR-BI ectopic expression would restore HCV
infection has been available.
Aiming to directly address these different possible functions of
SR-BI in HCV entry, we report here for the first time a sensitive
functional complementation assay that allows studying this
molecule by mutagenesis. By screening cells of human and non-
human origins for absence or low SR-BI expression in which HCV
entry could be restored by SR-BI ectopic expression, our data
highlight one non-hepatoma human cell line and one hepatoma
rat cell line in which HCV entry assays could be performed. Our
results therefore clearly demonstrate that SR-BI is an essential
entry factor, along with CD81 and CLDN1, mediating HCV
entry. This is also the first report showing that HCV can enter
non-human cells upon expression of HCV receptors. Importantly,
we show that the selective lipid transfer properties of human SR-
BI were fully functional in such heterologous cell backgrounds,
allowing us to directly address the role of specific residues of SR-BI
ecto- and endo-domains in HDL-mediated infection-enhance-
ment.
How HCV undergoes cell penetration following binding to its
specific receptors remains ill defined. SR-BI alone or, alternatively,
SR-BI interacting with the other HCV receptors may initiate cell
penetration and/or mediate virus internalization. That HCVcc
binds SR-BI-expressing CHO cells but not CD81-expressing
CHO cells [9] may imply that a first contact with SR-BI is
necessary before the viral particle can interact with CD81. SR-BI
may induce HCV endocytosis by itself, as suggested by its capacity
to mediate internalization of its natural ligands [21,60,61].
Interestingly, expression of SR-BII, a mRNA splice variant that
differs from SR-BI at the C-terminus [18], which confers
intracellular localization of SR-BII and rapid internalization of
HDL [19,47], reduces HCVpp entry as compared to SR-BI (this
report). Along with findings of others, i.e., via SR-BII over-
expression in Huh-7 cells [59], this indicates that SR-BI, rather
than SR-BII, is a preferred receptor for HCV entry and that
determinants of SR-BI cytoplasmic tail different from those
controlling its endocytosis may regulate HCV entry. Additionally,
deletion (DCterm mutant) or replacement (SR-BI/CD36 chimera)
of SR-BI cytoplasmic tail also reduced its capacity to mediate
HCV entry. Moreover, functional restoration of the SR-BII
dileucine endocytic motif in the SR-BI C-terminal cytoplasmic tail
(SES mutant), which induces rapid internalization of SR-BI/HDL
complexes [51], did not increase HCV entry but rather reduced it.
Altogether, these results suggested that if SR-BI initiates and/or
promotes HCV endocytosis, it could be through its interaction
with other HCV entry factors rather than via a classical binary
virus/receptor complex.
In agreement with this assumption, our data raise the possibility
that determinants of the C-terminal cytoplasmic tail contribute to
SR-BI HCV entry functions through modulation of its intracel-
lular trafficking and/or membrane localization. The study of the
DAKL mutant, which abrogates SR-BI interaction with PDZK1
that modulates its intracellular transport, localization, assembly
and scaffolding [49,50], did not affect HCV entry, consistent with
the lack of effect of PDZK1 down-regulation in Huh-7 cells.
However, as suggested by results with the 2CS mutant (C462S-
C470S), which prevents SR-BI palmitoylation [46] and thus its
potential association to lipid raft micro-domains, our results
indicate that localization of SR-BI in specific micro-environments
could play a role in HCV entry. Indeed, sub-cellular fractionation
experiments showed that SR-BI localizes in plasma membrane
lipid rafts [62] and/or caveolae [63], which may play a critical role
in SR-BI-mediated transfer of lipids between HDL and cells
[64,65] and, possibly, HCV entry. Such low-density membrane
microdomains are enriched in cholesterol and glycolipids, and
have been involved in a number of transport and signaling events
that could be important for virus endocytosis and intracellular
transport [66].
Our study of SR-BI ectodomain mutants provides the first
direct and functional evidence that HCV and HDL binding to SR-
BI, and intact lipid transfer properties of SR-BI are required for
SR-BI function as HCV entry factor. SR-BI-mediated uptake of
HDL CE is a two-step process that requires high-affinity binding
of HDL followed by incorporation of CE to the plasma membrane
pool and subsequent transfer of the lipid to an inaccessible pool.
CE uptake is followed by hydrolysis to free cholesterol by a neutral
CE hydrolase. SR-BI-mediated lipid uptake leads to increase of
cholesterol content of the target cell membrane [22,23,65] and
activates distinct signaling pathways [67], which may provide
different beneficial roles for HCV entry.
First, using liposome-based in vitro fusion assays, HCVpp
membrane fusion was shown to be facilitated when cholesterol is
present in the target membrane [15]. By analogy with fusion
processes of Flaviviruses and Alphaviruses that have been widely
studied [68], cholesterol-enrichment of target membranes may
Figure 5. HCVpp entry in BRL3A-CD81-CLDN1 cells expressing SR-BI ectodomain mutants. (A) Cell surface expression (white bars) and
sE2 binding (black bars) of SR-BI mutants/isoforms as determined using anti-SR-BI antibody (CLA-1 mAb) and soluble E2 protein (sE2), respectively.
The results of cell surface expression, analyzed by flow cytometry of BRL3A-CD81-CLDN1 living cells transduced with retroviral vectors carrying the
indicated SR-BI mutants, are expressed as the average percentages of GEOmean (geometric mean) fluorescence shifts (mean6SD; n=3) detected
between mutant receptor–expressing cells and parental (—) cells, relative to cells expressing wild-type SR-BI (ca. 20-fold of GEOmean shift, see
Figure 1A) set to 100. The results of sE2 binding are expressed as the average percentages of GEOmean fluorescence shifts (mean6SD; n=3)
detected in parental BRL3A cells (—) or in BRL3A cells only expressing the indicated SR-BI mutants that were incubated with sE2-containing medium
vs. sE2-free medium, relative to cells expressing wild-type SR-BI (ca. 10-fold of GEOmean shift, see Figure 6) set to 100. Cell surface expression of SR-BI
mutants in these latter cells was similar to that detected in the SR-BI-expressing BRL3A-CD81-CLDN1 cells (data not shown). Cell surface expression of
SR-BI-Short (*, data not shown) was verified by immuno-blotting using an antibody against SR-BI C-terminus (400-104, Novus) on surface-biotinylated
proteins that were purified with streptavidin-coated beads. (B) Effect of SR-BI mutations on infectivity of HCVpp produced in serum-free media. The
results of infectivity (mean6SD; n=5) are expressed relative to the infectious titers of HCVpp or of control VSV-Gpp particles determined on wt SR-BI–
expressing BRL3A-CD81-CLDN1 cells (input ca. 10
4 GFP i.u.), set to 100. (C) Results of HCVpp infection-enhancement induced by HDL (6 mg/ml
cholesterol-HDL), expressed as ratios between average infectious titers determined in the presence or absence of HDL (mean6SD; n=5). No changes
of infectivity of VSV-Gpp control particles were detected under these experimental conditions (data not shown), as reported previously [25]. (D)
Relative capacities of SR-BI mutants to mediate HDL-CE uptake (black bars) and free cholesterol efflux (white bars) relative to wt SR-BI set to 100
(mean6SD; n=3). ND, not determined.
doi:10.1371/journal.ppat.1000310.g005
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interactions of HCV fusion protein. Alternatively, local cholesterol
enrichment may facilitate binding [69] and/or conformational
changes [70] within the HCV glycoproteins that are required for
membrane fusion processes.
Second, HCVpp internalization was shown to be specifically
accelerated by HDL [27]. As discussed above, this effect is likely to be
indirect. Indeed, the internalization rate of HCVpp is significantly
slower than that of pseudo-particles harboring the surface glycopro-
teins from murine leukemia virus, influenza virus [27], Semliki forest
virus, or vesicular stomatitis virus [11], and has an half-life much
longer than that of HDL internalization [71]. Furthermore, HDL
added during the initialstage ofinfection suppresses anone-hour time
lag during which cell-bound virions are not internalized [27]. This
may reflect the time interval required to assemble a functional HCV
receptor complex, which may be reduced upon SR-BI activation
through modifications of the cell membrane. A possibility is that
HDL/SR-BI interaction augments the rate of CD81 recruitment at
virion-binding sitesand/or internalization of HCV/CD81 complexes
via a cholesterol-dependent pathway. In agreement with this
assumption, that SR-BI mutants increasing internalization (SR-BII
and SES mutant) are less effective than wt SR-BI to mediate HCV
entry (see above) suggests that HCV internalization is likely driven by
SR-BI interacting with other receptors rather than via SR-BI alone.
In this respect, it is interesting that CD81 and SR-BI function
cooperatively to initiate HCV infection [32,72], that CD81-mediated
HCVentryseemsdependentonmembranecholesterol[72],andthat
SR-BI/HDL-mediated HCV entry enhancement stillrequires CD81
[25,27]. Interestingly, both SR-BI and CD81 have been proposed as
cell factors allowing Plasmodium sporozoite invasion and/or intracel-
lular parasite development in mouse [73] and human [74]
hepatocytes, perhaps through SR-BI-induced regulation of the
organization of CD81 at the plasma membrane by mediating an
arrangement permissive to penetration by sporozoites [73]. Yet,
although SR-BI lipid transfer blockers, i.e., SR-BI antibodies and
BLTs, reduce both Plasmodium and HCV infection [25,29,74], there
seems to be important differences in the mechanisms involved.
Indeed, in contrast to HCV surface glycoproteins, Plasmodium
sporozoites do not seem to directly interact with SR-BI and/or
CD81 [73,75]. Furthermore, in contrast to HCV, Plasmodium
sporozoites invasion is not enhanced by HDL [74]. Finally, while
we demonstrated that cholesterol uptake mediated by SR-BI
ectopically expressed in BRL3A-CD81-CLN1 cells is functional
(Figure 2C), we did not notice up-regulation of CD81 cell surface
expression and TEM localization whetherthese cells expressed ornot
SR-BI and following treatment with HDL (Figure S2 and data not
shown), in contrast to other studies that revealed such CD81 changes
in mouse hepatocytes [73]. These differences may reflect dissimilar
properties of mouse vs. human SR-BI and CD81, of species-specific
cholesterol transport processes and/or of the cellular backgrounds
used [76]. Likewise, no CD81 changes could be detected in Huh-7
cells incubated in the presence or in the absence of HDL (Figure S2).
Consistently, HDL did not enhance sE2 binding capacity to SR-BI
and/or CD81 (Figure 6). Finally, recent results of others suggest that
the association of CD81 with TEM is not essential for HCV entry (Dr
Jean Dubuisson, Personal Communication). Alternatively, homo-
oligomerization of SR-BI seems associated with functional expression
of the selective HDL cholesteryl ester uptake pathway [77] and may
contribute to the formation of a HCV receptor complex.
Third, an essential component of HDL that seems responsible
for infection enhancement at the level of HCV membrane fusion is
the apolipoprotein C-I (ApoC-I) [28,35], an exchangeable
apolipoprotein that could be transferred from HDL to the HCV
membrane during SR-BI-mediated lipid transfer and could
predispose HCV envelope for fusion with a target membrane,
via alterations of its outer phospholipid layer [35].
Further analysis of the HCV entry events mediated by HCV
receptors and co-factors will be greatly facilitated by the
availability of the novel functional receptor-complementation
assay described in this report. Moreover, it opens the way to
develop small animal models susceptible for HCV in which entry
inhibitors can be tested in vivo.
Materials and Methods
Cell lines
Huh-7 [78], PLC/PRF/5 human hepatoma (ATCC CRL-
8024), Hep3B human hepatocellular carcinoma (ATCC HB-
8064), BRL3A rat hepatocytes (ATCC CRL-1442) and 293T
(ATCC CRL-1573) cells were grown in DMEM (Invitrogen)
supplemented with 10% fetal bovine serum (FBS) (Invitrogen).
Fu5AH rat hepatoma cells [79] were grown in Eagle’s MEM
supplemented with 1% L-glutamine and 5% newborn calf serum.
CHO (ATCC CRL-1582) and SK-Hep1 (ATCC HTB-52) cells
were maintained in RPMI (Invitrogen) with 10% FBS.
Expression constructs and establishment of cells lines
expressing CLDN1, CD81, and SR-BI wt/mutants
Retroviral vectors expressing human CD81 (GenBank accession
number: NM_004356), Claudin-1 (NM_021101) and SR-BI
(Z22555) or mutant SR-BI receptors were inserted in CNC
MLV (murine leukemia virus) vector backbones (kind gift of M.
Collins) harboring selectable marker genes for blasticidin,
neomycin and hygromycin respectively. Construct details are
available upon request. The CD36 was kindly provided by Brian
Seeds [80]. The cDNAs encoding the SR-BI-Short [18] and SR-
BII [47,48] were based on the original sequence of human SR-BI
[18] and were inserted in the CNC expression vector. The SRBI-
CD36 [44,45,46], the DCterm [45], DAKL [49], SES [51]
chimeras were previously described for rodent SR-BI and were
used to derive the equivalent human SR-BI chimeras investigated
in this work. Point mutants encoding the following SR-BI
receptors: M159R, N173G, Q402R, E418R, Q402R-E418R,
G420H-G424H, C462S-C470S (2CS) [46,52,54,55,56,57] and
E210G (MD and FLC, unpublished data), were introduced in
human SR-BI cDNA by site directed mutagenesis (primer
sequences are available upon request). All mutants were sequenced
to ensure that the clones possessed only the expected mutation.
Retroviral vectors containing CD81, CLDN1 and wt or mutant
SR-BI receptors were produced from 293T cells as VSV-G-
pseudotyped particles as described previously [81,82]. Stable
expression of either receptor in target cells was obtained by
transduction with vector particle-containing supernatants of 293T
producer cells, followed by antibiotic selection.
Figure 6. Inhibition of sE2 binding to SR-BI by BLT-4 compound. BRL3A cells expressing the indicated entry factors were incubated for 1 hr at
37uC with soluble E2 protein (sE2) (plain lines) or without sE2 (dotted lines) at saturating concentrations, after pre-incubation for 45 min at 37uC with
(gray lines) or without (black lines) 50 mM BLT-4 (Chembridge), a SR-BI inhibitor [53], and with (left panels) or without (right panels) HDL (6 mg/ml
cholesterol-HDL). SR-BI expression was not modified by the incubation with BLT-4 (data not shown). The data are representative of three
independent experiments.
doi:10.1371/journal.ppat.1000310.g006
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The expression vector for the E1E2 glycoproteins of HCV strain
H77 (AF009606) was described previously [33]. Viral pseudo-
particles named HCVpp and VSV-Gpp harboured the glycoproteins
of HCV and VSV, respectively, and were produced as described
previously [33] by transfection in 293T cells of vectors encoding viral
glycoproteins, packaging proteins, and GFP-transfer vector. Prior to
harvest viral particles-containing supernatants, producer cells were
incubated in DMEM containing 0.1% FCS for 24 hrs.
For infection assays, target cells were seeded 24 hr prior to
inoculation. 2 hr prior to infection, target cells were pre-incubated
in DMEM containing 0.1% FCS. Then medium was removed and
dilutions of viral supernatants were added to the cells and
incubated for 4 hr. Where indicated, HDL (Calbiochem) was
added to the infection reactions at 6 mg/ml of cholesterol.
Supernatants were then removed and the infected cells kept in
regular medium (DMEM, 10% FCS) for 72 hr before analysis of
the percentage of GFP-positive cells by FACS analysis [33]. The
infectious titers were expressed as GFP infection units (i.u.) per ml
of HCVpp-containing medium. Infections were controlled by
using non-enveloped particles, which resulted in background titers
between 10
2 and 10
3 GFP i.u./ml.
Production of HCVcc and infection assays
Plasmid pJFH-1 displaying previously described mutations
F172C and P173S in core, as well as N534K in E2 [83], was in
vitro transcribed using the Megascript T7 kit (Ambion). After
DNAse treatment, genomic RNA was purified by two acidic
phenol/chloroform extractions and pelleted by isopropanol
precipitation. Then, RNA was electroporated into Huh-7.5 cells
using Gene Pulser II apparatus (Biorad) and cells were cultured
under standard conditions. Virus-containing medium was har-
vested, pooled and added to target cells as described above. Where
indicated, HDL (Calbiochem) was added to the infection reactions
at 0.6 mg/ml of cholesterol.
Infected cells were collected by trypsinization, and RNA was
prepared (RNeasy; QIAGEN), reverse transcribed (iScript cDNA
synthesis kit, Biorad) and quantified with HCV specific (59-
CTTCACGCAGAAAGCGTCTA and 59-CAAGCACCCTAT-
CAGGCAGT) and house-keeping primers targeting RSP11 in SK-
Hep1 and Huh-7 cells (59-GCCGAGACTATCTGCACTAC and
59-ATGTCCAGCCTCAGAACTTC) or rat GAPDH in BRL3A
cells (59-GTTACCAGGGCTGCCTTCTC and 59-GGGTT-
TCCCGTTGATGACC) using the Platinum SYR Green qPCR
super mix kit from Invitrogen on an Applied 7000 apparatus.
Binding and surface staining assays
Binding of soluble E2 glycoprotein, derived from the H77-E2
was performed as previously described [27,38]. Briefly, 5 mg/ml of
sE2 harbouring a His-tag was incubated for 1 hr at 37uC with 10
6
target cells. The amount of cell-bound sE2 was determined by
FACS analysis using 2 mg/ml of an anti-His tag antibody
(pentaHis, Qiagen) and using Allophycocyanine (APC)-conjugated
anti-mouse antibodies.
The surface expression of hCD81 and hSR-BI was quantified
by FACS analysis from 10
6 live cells using anti-CD81 mAb (clone
JS81, Pharmingen) and anti-SR-BI mAb (CLA-1, BD Biosciences),
respectively, added to cells for 1 hr in PBFA at 4uC. After washing,
the binding of antibody to the cell surface was detected using RPE-
or APC-conjugated anti-mouse antibodies.
Lipid transfer assays
Lipid efflux assays were performed as previously described [37].
After plating, cells were labeled by incubation with
3H-cholesterol
(1 mCi/ml) for 48 hr. Subsequently cells were incubated for 24 hr
in the presence of BSA (0.5%) and newborn calf serum (25%) for
Fu5AH or fetal bovine serum (25%) for BRL3a or SK-Hep1, to
allow equilibration of the label. After equilibration, cholesterol
acceptors (20 mg phospholipid/ml of isolated HDL) were added in
serum-free medium and incubated with cells for 4 hr at 37uC.
Fractional cholesterol efflux (expressed as percentage) was
calculated as the amount of the label recovered in the medium
divided by the total label in each well (radioactivity in the
medium+radioactivity in the cells) obtained after lipid extraction
from cells in a mixture of 3:2 hexane-isopropanol (3:2 v/v). The
background cholesterol efflux obtained in the absence of
cholesterol acceptor was subtracted from the efflux values obtained
with the test samples.
Selective HDL-CE (cholesteryl ester) uptake was performed as
previously described [36]. Cells were plated in 24-well tissue
culture plates (10
6 cells/well). Two days after plating, cells were
washed 3 times with PBS and once with serum-free medium. Cells
were subsequently incubated in the presence of
3H-CE-labelled
HDL (60 mg protein) diluted in serum-free medium at 37uC for
5 hr. At the end of incubation, the medium was removed and cells
were washed 4 times with PBS and incubated in the presence of an
excess of unlabelled HDL (100 mg protein) for 30 minutes. Cells
were then washed 4 times with PBS and solubilized with 200 mlo f
NaOH 0.2 N for 15 minutes at room temperature with gentle
mixing. Protein content (20 ml) from each well was measured using
the Bicinchoninic acid protein reagent (Pierce). The radioactive
content of 100 ml of each cell lysate was measured by liquid
scintillation counting. Selective uptake was calculated from the
known specific radioactivity of radiolabelled HDL-CE and is
expressed in mg HDL-CE/mg cell protein.
Supporting Information
Figure S1 HCVpp entry in receptor-complemented BRL3A or
SK-Hep1 cells. (A) Western blot analysis of the indicated HCV
receptors in lysates of BRL3A, SK-Hep1, and Huh-7 cells ectopically
expressing (+) or not expressing (2) the indicated HCV receptors
usingSR-BI(CLA-1,BDBioscience),CD81(JS81,Pharmingen),and
CLDN1 (mouse anti-Claudin-1, Interchim) antibodies. The endog-
enous rat orthologs of these molecules were detected in BRL3A,
Fu5AH rat hepatoma cells, and Huh-7 cells (Huh-7*, Fu5AH*, and
BRL3A*) by Western blot analysis using cross-reactive antibodies
against SR-BI (400-104, Novus), CD81 (EAT-2, Santa Cruz
Biotechnology), and CLDN1 (mouse anti-Claudin-1, Interchim)
antibodies. The actin staining (mAb AC74, Sigma-Aldrich) was used
to ensure equal input of cell lysates. (B) Abundance of rat (white bars)
and human (black bars) SR-BI mRNA levels in Fu5AH, BRL3A,
BRL3A-CD81-CLDN1, and BRL3A-CD81-CLDN1-SR-BI cells.
Total RNA was then extracted, quantified by Real time quantitative
PCR, and normalized to rat b-Gus housekeeping gene (Protocol S1).
Expression data were corrected for PCR efficiencies of the target and
the reference gene, thus making possible analysis of the expression of
one gene relative to the others. (C) Results of HCV entry assays on
BRL3A-CD81-CLDN1-SR-BI, BRL3A-CD81-CLDN1, and Huh-7
target cells using HCV pseudo-particles carrying a luciferase marker
gene and harboring E1E2 glycoproteins derived from the indicated
genotypes/subtypes 1a (H77), 1b (Con-1, UKN1B 12.16), 2a (JFH-1,
UKN2A 2.4), 2b (UKN2B 2.8), and 3a (UKN3A 1.28), as indicated
[15], control viral particles harboring the VSV-G glycoprotein
(diluted 1/100) or no glycoprotein (noENV). Results display average
infectious titers, expressed as Luciferase unit (RLU) per 10
5 target
cells (mean6SD; n=3). (D) Results of HCV entry assays on BRL3A
(left panel) and SK-Hep1 (right panel) cells ectopically expressing the
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H77-E1E2 glycoproteins (HCVpp), control viral particles harboring
the VSV-G glycoprotein (VSV-Gpp), or no glycoprotein (noENVpp).
The viral particles, containing a GFP marker gene, were produced in
cellculture media devoid of serum lipoproteins.Results are expressed
as percentages of the infectious titers (mean6SD; n=3) determined
in BRL3A cells expressing CD81, CLDN1, and SR-BI (titer: 2610
4
i.u./ml) and SK-Hep1 expressing CD81, CLDN1, and SR-BI (titer:
5610
4i.u./ml).Asindicated,HCVppentryassayswereperformed in
the absence (2)o ri nt h ep r e s e n c e( H D L )o f6mg/ml cholesterol-
HDL. No changes of infectivity with VSV-Gpp control particles were
detected under these experimental conditions (data not shown), as
reported previously [25].
Found at: doi:10.1371/journal.ppat.1000310.s001 (0.19 MB TIF)
Figure S2 Cell surface expression of hCD81 and/or hSR-BI in
BRL3A cells. BRL3A cells expressing the indicated entry factors
were pre-incubated for 2 hrs in low serum-containing medium
(0.1%), then incubated for 1 hr at 37uC in the absence (black lines)
or in the presence (gray lines) of HDL (6 mg/ml cholesterol-HDL)
before staining with JS81 (left panels) or CLA-1 (right panels)
antibodies. The background of fluorescence was provided by
staining the cells with the secondary antibodies only (dotted lines).
Found at: doi:10.1371/journal.ppat.1000310.s002 (0.37 MB TIF)
Figure S3 HCV entry in PDZK1 down-regulated target cells.
PDZK1 (GenBank accession number: NM_002614) down-regula-
tion was induced upon expression of specific shRNAs (PDZK1-1:
59-GCTATGGCTTTCACTTAAAT and PDZK1-2: 59-GAAA-
GAAGGCCTATGATTA) via the FG12 lentiviral vector [84]
introduced in Huh-7 target cells. As controls, Huh-7 cells were
transduced with FG12-derived vectors carrying shRNAs for
CLDN1 (59-AAGTGCTTGGAAGACGAT) and CD81 (59-
GATCGATGACCTCTTCTCC) or were left intact (2). (A)
Western blot analysis of PDZK1 in lysates of Huh-7 cells in which
these shRNAs were expressed (rabbit polyclonal Ab NB 400-1491,
Novus Biologicals). The actin staining (mAb AC74, Sigma-Aldrich)
was used to assess cell density. (B) Results of HCV entry assays on
Huh-7 cells expressing PDZK1 or control shRNAs using HCV
pseudo-particles harboring H77-E1E2 glycoproteins (HCVpp),
control viral particles harboring the RD114 glycoprotein
(RD114pp), or no glycoprotein (noENVpp). The viral particles,
containing a CD90 marker gene, were produced in cell culture
media devoid of serum lipoproteins. The results of infectivity
(mean6SD; n=3) are expressed relative to the infectious titers of
HCVpp or of control RD114pp determined on intact Huh-7 cells,
which were determined 72 hr after infection by measuring CD90
reporter gene expression by FACS analysis using an allophycocya-
nin (APC)-conjugated anti-CD90 mAb (clone 5E10, BD Pharmin-
gen). As indicated, HCVpp entry assays were performed in the
absence (2) or in the presence (HDL) of 6 mg/ml cholesterol-HDL.
Found at: doi:10.1371/journal.ppat.1000310.s003 (0.09 MB TIF)
Figure S4 HCVpp entry in SK-Hep1-CLDN1 cells expressing
SR-BI mutants. (A) Cell surface expression (white bars) of SR-BI
mutants/isoforms as determined using anti-SR-BI antibody (CLA-
1,BDBioscience). The results ofcellsurfaceexpression,analyzed by
flow cytometry of SK-Hep1-CLDN1 cells transduced with
retroviral vectors carrying the indicated SR-BI mutants, are
expressed as the average percentages of GEOmean (geometric
mean) fluorescence shifts (mean6SD; n=3) detected between
mutant receptor-expressing cells and parental (2) cells, relative to
cells expressing wild-type SR-BI (ca. 40-fold GEOmean shift,
Figure 1A) set to 100. Cell surface expression of CD36 (*, data not
shown) was verified using a CD36 antibody (FA6-152, abcam). Cell
surface expression of SR-BI-Short (*, data not shown) was verified
by immuno-blotting using an antibody against SR-BI C-terminus
(400-104, Novus) on surface-biotinylated proteins that were purified
with streptavidin-coated beads. (B) Effect of SR-BI mutations on
infectivity of HCVpp produced in serum-free media. The results of
infectivity (mean6SD; n=5) are expressed relative to the infectious
titers of HCVpp or of control VSV-Gpp particles determined on wt
SR-BI-expressing SK-Hep1-CLDN1cells(inputca.10
4 GFPiu),set
to 100. (C) Results of HCVpp infection-enhancement induced by
HDL (6 mg/ml cholesterol-HDL), expressed as ratios between
average infectious titers determined in the presence or absence of
HDL (mean6SD; n=5). No changes of infectivity of VSV-Gpp
control particles were detected under these experimental conditions
(data not shown), as reported previously [25].
Found at: doi:10.1371/journal.ppat.1000310.s004 (0.13 MB TIF)
Protocol S1 Supplementary Materials and Methods
Found at: doi:10.1371/journal.ppat.1000310.s005 (0.03 MB
DOC)
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